Authors: Ziembicki H et al.
Cureus 17(9):e91962, September 10, 2025. DOI: 10.7759/cureus.91962
Remimazolam is an emerging ultra–short-acting benzodiazepine designed to address the major limitations of midazolam in procedural sedation. Unlike midazolam, it does not produce active metabolites and is rapidly hydrolyzed by tissue esterases, creating a predictable onset, quick offset, and faster recovery with far less risk of prolonged sedation. This narrative review evaluates its pharmacology, safety, and clinical performance using evidence from 2015–2025.
Remimazolam works on GABAA receptors much like midazolam but with faster metabolism and considerably less variability in patient response, making titration easier and recovery more reliable. Because it produces minimal cardiovascular depression—especially compared with propofol—it may offer a safer option for sedation in elderly patients, those with cardiac disease, or any setting where hemodynamic stability is crucial. Flumazenil fully reverses its effects, with a significantly lower risk of re-sedation compared with midazolam.
Across clinical trials, remimazolam consistently provides quicker induction, shorter procedures, and faster discharge readiness than midazolam. Studies comparing it with propofol demonstrate far less hypotension, bradycardia, and respiratory depression. Compared with ketamine, remimazolam avoids dissociation, agitation, and emergence reactions while still providing adequate sedation. Its main limitations currently include incomplete dosing consensus, higher cost than older sedatives, and a relatively small volume of long-term safety data.
Overall, the review highlights remimazolam as a promising sedative that combines rapid pharmacokinetics with excellent hemodynamic stability and full reversibility—properties that support its increasing use for short procedures, outpatient work, and sedation in patients with fragile physiology.
What You Should Know
• Remimazolam is ultra–short-acting with no active metabolites, giving it faster and more predictable recovery than midazolam.
• It causes far less hypotension or respiratory depression than propofol and avoids ketamine’s emergence reactions.
• Flumazenil reliably reverses its effects with minimal risk of re-sedation.
• Clinical trials show higher sedation success rates versus midazolam and fewer adverse events compared with propofol.
• The main barriers to widespread adoption remain cost, limited long-term data, and evolving dosing guidelines.
Thank you for allowing us to use this article from Cureus.